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Abstract
The matrix protein osteopontin has been shown to be a marker of osteoclastic activity in multiple myeloma
patients, as well as a regulator of angiogenesis. We measured serum levels of osteopontin in 50 untreated multiple
myeloma patients (in 25, also after treatment) and examined the relation to markers of osteolytic and angiogenic
activity. The median (range) of serum osteopontin was 85 (5-232) in the patient group vs. 36 (2-190) ng/ml in the
control group. Serum osteopontin levels were significantly higher in patients with advanced stage or grade of
myeloma disease. All patients with serum osteopontin levels >100 ng/ml had advanced stage (II or III) or high
grade bone disease, whereas stage I or low grade patients had serum osteopontin levels <100ng/ml. Serum
osteopontin levels significantly decreased after treatment. There was a positive correlation of osteopontin with the
bone turnover marker N-terminal propeptide of procollagen type I (NTx) and the angiogenic markers vascular
endothelial growth factor (VEGF) and bone marrow microvessel density (r: 0.35, 0.47 and 0.30 respectively, p <
0.05). These results support osteopontin as a dual marker of bone destruction and angiogenic activity in myeloma
patients. Osteopontin represents a useful biomarker for monitoring myeloma disease activity.
To the Editor
Osteopontin (Opn) is a non-collagenous matrix protein
responsible for the migration and attachment of osteo-
clasts to mineral matrix of bone surfaces [1]. Inv i t r o
studies suggest that Opn and vascular endothelial
growth factor (VEGF) cooperatively enhance angiogen-
esis in MM [2,3]. We compared the serum levels of
Opn with those of established markers of angiogenic
activity and bone destruction in 50 (23 males, median
age 68 y.o.) untreated MM patients and 25 healthy age
& sex-matched blood donors (median age 65 y.o.). In 25
patients, measurements were repeated after reaching
plateau phase with chemotherapy. Ethics approval and
informed consent from all subjects were obtained.
Osteopontin and VEGF were measured with a solid-
phase sandwich enzyme-linked immunosorbent assay
(Quantikine
®, R&D Systems Inc. Minneapolis MN,
USA). Bone marrow cellularity and percentage of
infiltration by myeloma cells was estimated in all
patients. Microvessel density (MVD) was assessed on
bone marrow sections after staining endothelial cells
with the anti-CD34 antibody (Immunotech, Marseille,
France) [4]. The N-terminal propeptide of procollagen
type I (Ntx) in urine was measured by a competitive
inhibition ELISA (Ostex International, Seattle, WA,
USA) [5]. Classification and regression tree (CART; Sal-
ford Systems, San Diego, CA, USA) analysis was used to
identify the Opn levels best associating with disease
parameters.
Opn among MM patients [median (range) 85 (5-232)
ng/ml] was higher than controls [36 (2-190) ng/ml] but
the difference did not reach statistical significance. How-
ever, Opn was significantly higher in 35 patients with
Stage II or III compared with 15 Stage I patients (p <
0.001) (Figure 1). Similarly, there was a marked differ-
ence in Opn according to disease Grade (Figure 2), with
increasing levels from Grades 0 to 3 (p = 0.006).
CART analysis determined Opn >100 ng/ml as predic-
tor of advanced MM disease. All 17 patients with Opn
* Correspondence: alexandm@med.uoc.gr
3Department of Hematology, University Hospital of Heraklion, Crete, Greece
Full list of author information is available at the end of the article
Sfiridaki et al. Journal of Hematology & Oncology 2011, 4:22
http://www.jhoonline.org/content/4/1/22 JOURNAL OF HEMATOLOGY
& ONCOLOGY
© 2011 Sfiridaki et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.>100 ng/ml had advanced stage (II or III), whereas all
15 stage I patients had Opn <100 ng/ml (Odds Ratio
1.5, 95% Confidence Intervals 1.2-2.0; p = 0.036 Fisher’s
Exact test). Similarly, high grade (2 or 3) MM was asso-
ciated with Opn >100 ng/ml (OR 1.9, 95% CI 1.2-2.9, p
= 0.001) (Table 1).
Opn correlated significantly with VEGF, MVD, Ntx
and disease infiltration (Spearman’s rho 0.47, 0.30, 0.35
and 0.45 respectively; p < 0.05). In 25 patients, Opn
decreased from a median 78 ng/ml to 45 ng/ml post-
chemotherapy (p < 0.05). MVD, Ntx, VEGF and infiltra-
tion by myeloma cells were also significantly reduced
post-treatment (p < 0.001).
Our results add to the weight of data supporting a
relationship between circulating Opn and bone marrow
angiogenesis in myelomatous disease. We have defined a
cut-off value (100 ng/ml) strongly associated with
a d v a n c e dM Md i s e a s ea n dg r a d eo fb o n ed e s t r u c t i o n .
This may prove useful in patient stratification. The
applicability of our findings in different patient popula-
tions (i.e. genetic background, treatments used, comor-
bidities, etc) awaits validation.
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Figure 1 Serum osteopontin levels (ng/ml) according to Durie-
Salmon stage in multiple myeloma patients. Columns: 25-75% of
values; bold line: median; whiskers: 95% confidence intervals. (* = p
< 0.01 by Kruskal Wallis test).
Figure 2 Serum osteopontin levels (ng/ml) according to grade
of bone disease (low grade = grades 0 and 1; total 23
patients, versus high grade = grades 2 and 3; total 27
patients). Columns: 25-75% of values; bold line: median; whiskers:
95% confidence intervals. (* = p < 0.01 by Kruskal Wallis test).
Table 1 Association of serum osteopontin levels with: A)
stage, and B) grade of Multiple Myeloma





Stage 1 15 0 1.5 (1.2-2.0)
Stage 2-3 18 17
B. Grade
Low (0-1) 23 0 1.9 (1.2-2.9)
High (2-3) 15 12
Serum osteopontin cut-off has been determined using classification and
regression tree analysis.
OR = Odds Ratio; CI = Confidence Interval.
Sfiridaki et al. Journal of Hematology & Oncology 2011, 4:22
http://www.jhoonline.org/content/4/1/22
Page 2 of 33. Caers J, Gunthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I,
Van Camp B, Vanderkerken K: The involvement of osteopontin and its
receptors in multiple myeloma cell survival, migration and invasion in
the murine 5T33MM model. Br J Haematol 2006, 132:469-477.
4. Alexandrakis MG, Pappa CA, Miyakis S, Sfiridaki A, Kafousi M, Alegakis A,
Stathopoulos EN: Serum interleukin-17 and its relationship to angiogenic
factors in multiple myeloma. Eur J Intern Med 2006, 17:412-416.
5. Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandidaki E, Alegakis A,
Margioris AN: Relationship between serum levels of vascular endothelial
growth factor, hepatocyte growth factor and matrix metalloproteinase-9
with biochemical markers of bone disease in multiple myeloma. Clin
Chim Acta 2007, 379:31-35.
doi:10.1186/1756-8722-4-22
Cite this article as: Sfiridaki et al.: Circulating osteopontin: a dual marker
of bone destruction and angiogenesis in patients with multiple
myeloma. Journal of Hematology & Oncology 2011 4:22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sfiridaki et al. Journal of Hematology & Oncology 2011, 4:22
http://www.jhoonline.org/content/4/1/22
Page 3 of 3